ClinicalTrials.gg
CompletedNCT06559527Updated Mar 30, 2025

A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

A Phase 1 interventional study of NNC0487-0111 in Diabetes Mellitus, Type 2, Obesity and Overweight, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S — 25 open to participants now, 29 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Novo Nordisk A/S.

Enrollment
347th of 428
42 · median 209
Started
2024
with 25 others
Phase 1
129 of 643
5 open now
Registered
607th of 643
by date

Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 347th largest by enrollment of the 428 interventional ones that give a count, is one of 26 that started in 2024, is one of 129 in phase 1, and was the 607th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

25 of the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

Novo Nordisk is developing the study medicine NNC0487-0111 to treat people living with type 2 diabetes and/or people living with overweight or obesity. The aim of this study is to see if blood levels of NNC0487-0111 are the same in people living with various degrees of reduced kidney function as for people with normal kidney function. Participants will be given one single injection by the study staff in a skinfold in their stomach using a pen device (NovoPen®4).

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18-80 years (both inclusive) at the time of signing the
  • (BMI) between 20.0 and 39.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening.
  • Meeting the pre-defined values based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation (2021) adjusted for the estimated individual body surface area (BSA);

    • Normal renal function - greater than or equal to 90 mL/min
    • Mild renal impairment - 60 - 89 (mL/min)
    • Moderate renal impairment - 30 - 59 (mL/min)
    • Severe renal impairment - less than 30 (mL/min) not requiring dialysis
    • End-stage renal disease (ESRD) - Requiring dialysis treatment
  • For ESRD: Participants requiring dialysis treatment should be on current treatment with haemodialysis.

Exclusion criteria

Exclusion Criteria:

  • Any disorder, unwillingness, or inability which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol.
  • Use of drugs known to affect including cephalosporin and aminoglycoside, antibiotics, flucytosine, cisplatin, cimetidine, trimethoprim, cibenzoline, and nitrofurantoin within 14 days or 5 half-lives, whichever is greater, before dosing the medicinal product (IMP).
  • Presence or history of any respiratory, metabolic, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions(except conditions associated with renal impairment or ESRD).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Mild Renal Impairment

    Participants with mild renal impairment (estimated glomerular filtration rate \[eGFR\] - 60 - 89 milliliter per min \[mL/min\]) will administer a single dose of NNC0487-0111 on Day 1.

    Drug: NNC0487-0111

  • Experimental
    Moderate Renal Impairment

    Participants with moderate renal impairment (eGFR - 30 - 59 mL/min) will administer a single dose of NNC0487-0111 on Day 1.

    Drug: NNC0487-0111

  • Experimental
    Severe Renal Impairment

    Participants with severe renal impairment (eGFR - less than 30 mL/min not requiring dialysis) will administer a single dose of NNC0487-0111 on Day 1.

    Drug: NNC0487-0111

  • Experimental
    End-Stage Renal Disease (ESRD)

    Participants with ESRD (requiring dialysis treatment) will administer a single dose of NNC0487-0111 on Day 1.

    Drug: NNC0487-0111

  • Experimental
    Normal Renal Function

    Participants with normal renal function (eGFR - greater than or equals 90) will administer a single dose of NNC0487-0111 on Day 1.

    Drug: NNC0487-0111

Interventions

  • Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.

06

What researchers measure

Primary outcomes

  1. AUC0111,0-∞,SD: Area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose

    Measured as hours\*nanomole per liter (h\*nmol/L).

    Time frame: From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 28)

Secondary outcomes

  1. Cmax,0111,SD: Maximum observed plasma NNC0487-0111concentration after a single dose

    Measured as nanomole per liter (nmol/L).

    Time frame: From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 28)

  2. tmax,0111,SD: Time to maximum observed plasma NNC0487-0111 concentration after a single dose

    Measured as hours.

    Time frame: From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 28)

  3. t½,0111,SD: Terminal half-life of NNC0487-0111 after a single dose

    Measured as hours.

    Time frame: From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 28)

  4. Vz/F0111,SD: Apparent volume of distribution of NNC0487-0111 after a single dose

    Measured as liter (L)

    Time frame: From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 28)

  5. CL/F0111,SD: Apparent clearance of NNC0487-0111 after a single dose

    Measured as liter per hour (L/h).

    Time frame: From baseline (Visit 2, Day 1, pre-dose) until completion of the end of study visit (Visit 9, Day 28)

  6. Number of treatment emergent adverse events (TEAEs)

    Measured as number of events.

    Time frame: From time of trial product administration (Visit 2, Day 1) until completion of the end of study visit (Visit 9, Day 28)

07

Study locations

1 site
  • Charité Research Organisation GmbH
    Berlin, 10117, Germany
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Feb 2025, 6 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 6 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2024
First posted
Aug 19, 2024
StartActual
Aug 20, 2024
Primary completionActual
Feb 24, 2025
CompletionActual
Mar 5, 2025
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06559527
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 19, 2024
Start date
Aug 20, 2024
Primary completion
Feb 24, 2025
Completion
Mar 5, 2025
Last update
Mar 30, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zenagamtide

Start the discussion